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Cutaneous leiomyomas, rare benign tumors originat-
ing from the arrector pili muscle of the hair follicle,
can be associated with the common uterine ®broids
in a syndrome called multiple cutaneous and uterine
leiomyomas. Multiple cutaneous and uterine leio-
myomas are inherited as an autosomal dominant
trait, providing an excellent opportunity for the
study of the common non-Mendelian manifestation
of isolated uterine ®broids. This study reports the
clinical and molecular characterization of an
extended family with multiple cutaneous and uterine
leiomyomas. Linkage analysis has shown that the dis-
ease in this family is linked to the recently reported
genetic locus for multiple cutaneous and uterine
leiomyomas, with a maximum two-point LOD score
of 4.453 for markers D1S2670, D1S2785, D1S547,
and D1S1609. The identi®cation of key recombina-
tion events has allowed us to re®ne substantially the
location of the genetic locus for multiple cutaneous
and uterine leiomyomas, from 14 cM to an interval
of 4.55 or 7.19 cM, depending on the ®nal phenotype
of a young family member in which one of the key
recombination events has occurred. In addition, we
provide a description of the interesting pattern and
progression of the skin phenotype in this four-gener-
ation kindred. The re®nement of the genetic locus
for multiple cutaneous and uterine leiomyomas and
the availability of an extended multigeneration pedi-
gree will facilitate the identi®cation of the mutated
gene responsible for multiple cutaneous and uterine
leiomyomas, which, in turn, may provide key infor-
mation for the understanding of the molecular basis
of the common uterine ®broids. Key words: genetic
locus for multiple cutaneous and uterine leiomyomas/ leio-
myoma. J Invest Dermatol 118:876±880, 2002
C
utaneous leiomyomas are benign tumors arising from
the arrector pili muscle of the hair follicle. They can
range in number from a few to several hundred. Skin
leiomyomas are found in association with uterine
leiomyomas in an autosomal dominant syndrome
called multiple cutaneous and uterine leiomyomas (MCL; MIM
150800) (Reed et al, 1973; Thyresson and Su, 1981; Valdivia et al,
1983; Garcia Muret et al, 1988; Fernandez-Pugnaire and Delgado-
Florencio, 1995; Fear®eld et al, 2000; Konig and Happle, 2000;
Alam et al, 2001). One of the main approaches for the elucidation
of the genetic components underlying a complex trait is the study
of related Mendelian disorders. Such is the case for the common
uterine leiomyomas (myomas or ®broids), where both genetic and
nongenetic factors are thought to play a part, and MCL, a
Mendelian disease.
Very recently, the locus responsible for MCL has been mapped
to an ~ 14 cM region on chromosome 1q42.3±43 (Alam et al,
2001). Moreover, the same locus has been identi®ed in a separate
study as the susceptibility locus for a hereditary cancer syndrome,
including renal cell cancer, as well as uterine and cutaneous
leiomyomas (Kiuru et al, 2001; Launonen et al, 2001). This study
reports the clinical and genetic ®ndings in an extended pedigree
with MCL. The clinical features of MCL in a new large family are
described in detail, with emphasis on the particular timing of the
appearance and progression of the skin lesions. Moreover, evidence
is provided for a case of type II segmental manifestation of
cutaneous leiomyoma within the family. The genetic analysis of this
pedigree has allowed us to narrow the location of the genetic locus
for multiple cutaneous and uterine leiomyomas (MCUL1) to a
region of 4.55±7.19 cM on chromosome 1.
MATERIALS AND METHODS
Patients Forty-three family members of a large Israeli family with
MCL were interviewed and examined by two physicians. Photographs
were taken during these meetings and blood samples collected following
informed consent. Four family members, II-3, III-8, III-9, and IV-14
(Fig 1), were available only for the interview and examination and one
member (II-1) only for blood collection. Skin and uterine involvement
of the offspring of II-1 was reported anecdotally by relatives. Biopsies
taken prior to this study from four affected patients con®rmed the
diagnosis of cutaneous (III-17, III-19, III-21, and IV-5) and uterine (III-
17, III-19) leiomyomas.
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Linkage analysis Blood samples were collected from 40 family
members and genomic DNA was extracted using the PureGene DNA
Isolation Kit (Gentra Systems, Minneapolis, MN). Two genomic regions
were analyzed before embarking in a genome-wide scan: chromosome
18p, as monosomy for this chromosomal region has been described in a
patient with mental retardation and multiple cutaneous leiomyomas, and
the MCUL1 locus, on chromosome 1q. Microsatellite markers covering
these regions were chosen from the genetic map at the Center for
Medical Genetics, Marsh®eld Medical Research Foundation (Broman et
al, 1998), and the sequences for their polymerase chain reaction (PCR)
primers obtained from the Genome Database and the Cooperative
Human Linkage Center. The (PCR) ampli®cation products were
resolved on 6% nondenaturing polyacrylamide gels and visualized by
ethidium bromide staining.
Two-point, multipoint, and haplotype analyses were performed on the
pedigree. For all linkage analyses, a dominant model with age-dependent
penetrance was assumed. Seven liability classes were de®ned as follows:
age 0±10, 0.001; age 11±20, 0.500; age 21±30, 0.700; age 31±40, 0.800;
41±50, 0.900; 51±60, 0.950; 61 or older, 1.000. The disease allele was
assumed to have a frequency of 0.001. The marker-allele frequencies
were estimated from the data using observed and reconstructed genotypes
of founders within the pedigrees. To avoid computation errors due to
observed allele frequencies of 0.0, marker alleles for all markers were re-
coded using the RECODE program (Weeks, 2000). This re-coding
program insured that alleles were numbered sequentially, and that every
allele frequency was nonzero. In addition, the re-coding had no effect
on any of the analyses, in terms of power of the methods.
Two-point analyses were carried out using the MLINK program of
the FASTLINK suite of programs (Lathrop et al, 1984; Cottingham et al,
1993; Schaffer et al, 1994). LOD scores were computed for q
(recombination fraction) values ranging over the interval (0.0, 0.5) in
increments of 0.02, as well as q = 0.05. In the interest of brevity, only a
small number of LOD score values for each marker locus are reported
(Table I).
Multipoint and haplotype analyses were carried out using the
SIMWALK program version 2.8 (Sobel and Lange, 1996). This software
was chosen because it employs a Markov chain Monte Carlo approach,
which allows for both a large number of founders in a pedigree and
multiple markers in the computation of LOD scores. Markers were
chosen for the multipoint analysis according to the following steps: (i) all
markers that showed 0.0 recombination fractions with other markers
according to the Marsh®eld genetic map (Broman et al, 1998) were put
into distinct groups, and (ii) among markers in the distinct groups, those
markers with the largest heterozygosity were chosen for multipoint
analysis. This procedure was followed as the method used in SIMWALK
has computational limitations for markers with 0.0 recombination
distances (E. Sobel, personal communication). As a result of this
procedure, two markers, D1S2670 and D1S547, were excluded from the
multipoint and haplotype analyses. Recombination distances between
markers were computed using the sex-averaged Marsh®eld genetic map
(Broman et al, 1998). For haplotype analysis, we used the same set of
markers as those used for multipoint analysis. Informative recombination
events are discussed in Results.
Family members with cutaneous leiomyomas were classi®ed as
affected. All individuals younger than the age of onset of their affected
parent were scored as unknown. Finally, although II-1 and II-5 had
affected offspring, they were also classi®ed as unknown, as they were not
examined by the authors and clinical records on the skin involvement
were not available.
Electronic database information The URL for the databases used in
this study are as follows:
Center for Medical Genetics, Marsh®eld Medical Research Foundation,
http://research.marsh®eldclinic.org/genetics/
Cooperative Human Linkage Center, http://lpg.nci.nih.gov/CHLC
Ensembl Genome Server, http://usensembl.org
GeneMap'99, http://www.ncbi.nlm.nih.gov/genemap99/
Genome Database, The, http://www.gdb.org
Human Genome Project Working Draft, http://genome.ucsc.edu/
index.html
National Center for Biotechnology Information, http://www.ncbi.nlm.
nih.gov
RESULTS
Clinical ®ndings The individuals in this study belong to a four-
generation pedigree from Israel in which MCL is inherited in an
autosomal dominant manner (Fig 1). All patients reported
sensitivity to touch, and pain to cold exposure. Skin leiomyomas
were found in 10 individuals (six females and four males), ranging
in age from 18 to 65. In two additional family members, a history of
skin leiomyoma was reported by their relatives. In six of 10
patients, the disease started at age 18±20, whereas the rest
developed the disease at age 14 (V-12), 30 (IV-2), 45 (III-19),
and 55 (III-21). The lesions were ®rm, skin colored to pinkish-red,
ranged in number from few in the younger members to up to 100
in the oldest individual examined (III-17), and their diameter
ranged from 0.2 cm to 1.0 cm (Fig 2). The number of lesions
increased with time and became more grouped. The pattern of
progression was highly consistent among the patients. In six affected
members, the disease started on the left arm, where only two or
three leiomyomas were found (Fig 2a). In two other members,
two or three lesions ®rst appeared on the left anteromedial thigh
and then on the left arm. Following the left arm, a few lesions
appeared on the left upper back in nine of 10 patients, and then on
the right upper back in ®ve patients (Fig 2b), the right lower back
(Fig 2c), right arm, and right leg. The involvement of the right side
in patients who had a more prolonged disease (III-17, III-19, III-
21, IV-3, and IV-5) was more severe than on the left side. Patient
IV-13, aged 26 y, showed only involvement of the right arm (one
lesion) and the lower right abdomen (one lesion). Interestingly, the
major exception was V-12, a young female aged 18. She ®rst
developed the disease at an early age, 14 y old, with multiple
painful, ®rm, pale red skin lesions, of approximately 0.2±0.5 cm in
size, on the right shin followed by the right lower thigh. On
examination, at age 18, two pale painful lesions were also found on
the left upper arm and two on the left upper back in accordance
with the typical pattern observed in other family members.
Regarding the uterine involvement, two affected females, III-17
and III-19, underwent hysterectomy due to uterine myomas at ages
38 and 30, respectively. Individual IV-12 has myomas. Among the
rest of the affected females, II-5 suffered from abdominal pains and
died during labor due to suspected uterine tumor at age 34, and V-
12 suffered from menometrorrhagia. Individuals III-21 and IV-2
denied having myomas or related symptoms. Finally, III-9, the
Table I. Two-point LOD scores for chromosome 1q42.3±43 markers in the MCL pedigree
Marker
Genetic
location (cM)
LOD score at q =
0.00 0.01 0.05 0.1 0.2 0.3 0.4
D1S517 262.96 ± 17.24 2.38 2.80 2.73 2.26 1.61 0.85
D1S2670 262.96 4.45 4.38 4.07 3.68 2.83 1.91 0.94
D1S2785 266.27 4.45 4.38 4.07 3.68 2.83 1.91 0.94
D1S204 267.51 1.64 1.60 1.43 1.20 0.77 0.39 0.12
D1S547 267.51 4.45 4.38 4.07 3.68 2.83 1.91 0.94
GGAA27E08 272.27 0.47 0.47 0.45 0.43 0.37 0.27 0.15
D1S1609 274.53 4.45 4.38 4.07 3.68 2.83 1.91 0.94
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daughter of an unaffected mother, had a hysterectomy at age 28.
This case would be in accordance with the high prevalence of
uterine leiomyoma among women (Stewart, 2001). No other
diseases were reported in the family, except for patient III-17 who
suffered from an undiagnosed progressive neurologic disease.
Con®rmation and re®nement of the MCUL1 locus As an
initial step, prior to performing a genome-wide scan, we analyzed
the candidate loci on chromosomes 18p and 1q42.3±43 (MCUL1).
As monosomy for 18p had been described in a patient with mental
retardation and cutaneous leiomyoma (Fryns et al, 1985), we
performed a cytogenetic analysis in one of the patients, III-21, and
no chromosomal alterations were found. To de®nitively rule out
this chromosomal region we performed cosegregation analysis with
microsatellite markers covering chromosome 18p and found no
evidence of linkage (data not shown). These results are not
unexpected, as Turleau et al (1988) also excluded cytogenetic
abnormalities in three cases of MCL.
Analysis of the MCUL1 locus, on the other hand, provided
strong evidence in favor of linkage. To con®rm these results, we
typed a total of 12 markers in the region. A maximum two-point
LOD score of 4.453 was obtained for markers D1S2670, D1S2785,
D1S547, and D1S1609 (q = 0) (Table I). Multipoint analysis
supported linkage to this region, with a maximum multipoint LOD
score of 4.453 throughout the interval D1S2785±D1S1609.
Haplotype analysis revealed critical recombination events in two
family members, III-17 and V-2 (Fig 1). In III-17, an affected
female, a recombination event has occurred between markers
D1S517 and D1S2670. This recombination event identi®es the
same centromeric boundary as the one established in previous
reports (Alam et al, 2001; Launonen et al, 2001); however,
individual V-2, an unaffected 19 y old female, provides key
information to narrow the MCUL1 locus. As V-2 is too young, we
need to consider two alternatives. If V-2 does carry the disease
gene, the recombination event would narrow the MCUL1 locus
from 14 cM (Alam et al, 2001), to a 7.19 cM interval, between
markers D1S2785 (recombination in individual V-2, this study) and
D1S2842 (individual 302, from family ML304, in Alam et al, 2001).
If, on the contrary, V-2 does not carry the disease gene, we would
have narrowed the disease locus to a 4.55 cM interval, ¯anked by
markers D1S517 (recombination in individual III-17, this study)
and D1S204 (V-II).
DISCUSSION
The identi®cation of the MCUL1 locus as responsible for the
disease in the pedigree studied here, one of the largest MCL
kindreds reported up to now, provides strong evidence for the
Figure 1. Pedigree with MCL, showing the haplotypes for markers at 1q42.3±43. Black, gray, and empty symbols indicate family members
scored as affected, unknown, and unaffected in the linkage analysis, respectively. The order of the markers is indicated in the upper right corner. The
disease-associated haplotype is boxed. Genotypes in parentheses for family members II-5 and III-18 were inferred from their offspring. The genotype
for marker GGAA27E08 in individual V-4 could represent a mutation affecting the length of the microsatellite. Arrows indicate the meiotic
recombination events.
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genetic nature of the disease, inherited as an autosomal dominant
trait.
Both the age of onset and the pattern of clinical symptoms appear
to be consistent throughout the pedigree. Seven of 10 affected
individuals developed the disease before age 20. Two patients
claimed that the disease started at ages 45 (III-19) and 55 (III-21);
however, the location of the ®rst skin lesions in most of the family
members (see clinical ®ndings in Results) raises the possibility that
the ®rst lesions could go unnoticed by some patients. It is of interest
that patient III-19 was diagnosed to have uterine myoma since at
least age 30. This patient has eight unaffected children, aged 24±42.
As this is an extremely rare situation, with a probability of 0.4%, the
eight siblings were examined by two dermatologists and none was
found to be affected. Furthermore, all ®ve daughters denied any
history of abdominal pain, irregular bleeding, or an enlarged uterus.
The striking ®nding in this family is the relatively constant
pattern of progression of the skin lesions, from left to right, which
does not ®t any known skin patterning lines, such as Blashko's lines
(Happle, 1993). To our knowledge, this phenomenon was not
noticed previously, although the increased number of lesions with
time has been documented in some studies. Skin leiomyomas have
been classi®ed so far as solitary, segmental, dermatomal, or
disseminated; however, it is possible that this classi®cation could
be based on incomplete clinical observations. Patient V-12 is an
interesting case, as she may represent an example of type II
segmental leiomyomatosis (localized loss of heterozygosity or
LOH) superimposed upon familial disseminated cutaneous leio-
myomatosis. Previous reports have documented the earlier appear-
ance of segmental lesions in cutaneous leiomyoma (Happle, 1997).
According to Happle (1993), when disseminated and segmental
leiomyomatosis coexist, ``the lesions in the segmental pattern tend
to be more numerous and prominent than the other tumors present
in the same patient and his family members''. These observations
would explain both the early onset of the ®rst skin lesions in V-12,
at age 14, and the more severe manifestation observed in the
segmental involvement, compared with the rest of the affected
family members.
Of special interest is that pedigrees such as those reported by
Alam et al (2001), Launonen et al (2001), and this study, can provide
insights into more complex diseases, such as common uterine
leiomyomas, where a genetic predisposition is only suspected. The
susceptibility to uterine myomas is thought to have environmental,
hormonal, and genetic components (Stewart, 2001). In MCL,
however, uterine leiomyomas are clearly inherited in an autosomal
dominant fashion, with incomplete penetrance in some pedigrees
(Thyresson and Su, 1981; Valdivia et al, 1983; Garcia Muret et al,
1988; Fernandez-Pugnaire and Delgado-Florencio, 1995; Fear®eld
et al, 2000; Konig and Happle, 2000; Alam et al, 2001). Both
cutaneous and uterine leiomyomas have been associated with
several chromosomal abnormalities. A patient with severe mental
retardation and multiple cutaneous leiomyomas has been described
with 9p trisomy/18p monosomy (Fryns et al, 1985). Moreover,
about 40±50% of uterine leiomyomas are associated with chromo-
somal abnormalities in the tumors, with chromosomes 6, 7, 12, and
14 as the most frequently involved (see Ligon and Morton, 2001,
for a review). In addition, deletion of both COL4A5 and COL4A6
genes on the X chromosome have been identi®ed in esophageal
leiomyomatosis associated with Alport syndrome (Heidet et al,
1995; Ueki et al, 1998).
The most compelling evidence for a genetic basis of leiomyoma,
however, is the recent identi®cation of the MCUL1 locus on
chromosome 1q42.3±43, in a group of 10 families with multiple
cutaneous leiomyomas and uterine ®broids (Alam et al, 2001) and
the identi®cation of two pedigrees with the speci®c combination of
renal cell cancer and uterine and cutaneous leiomyomas linked to
the same locus (Kiuru et al, 2001; Launonen et al, 2001). In both
studies, LOH at the linked locus has been found in some of the
tumors, suggesting the possibility of an underlying tumor suppres-
sor gene.
In the report by Alam et al (2001) one of 11 families with MCL
was not linked to the MCUL1 locus. Although the possibility
remains that the genetic susceptibility to MCL is genetically
heterogeneous, the authors point to phenocopies or a diagnostic
error in the unlinked family as alternative explanations. Moreover,
both pedigrees studied by Launonen et al (2001), with the
combination of MCL and renal cancer are also linked to
MCUL1. Assuming genetic homogeneity, our results signi®cantly
re®ne the MCUL1 locus. As the key recombination event has taken
place in a young unaffected female, V-2, we must consider two
possible scenarios based on her de®nitive phenotype: the re®ne-
ment of the MCUL1 locus to a 7.19 cM interval, if V-2 does,
indeed, carry the mutated gene; or a considerably shorter interval of
4.55 cM if V-2 does not carry a mutated MCUL1 allele. Although
careful repeated clinical examination of V-2 did not reveal any sign
of the disease, she is still too young to draw any conclusion. Her
affected mother and brother developed the disease at ages 30 and
18, respectively. The age of onset in the family studied ranged from
14 to 55; however, six of 10 family members developed the disease
before age 18, and seven of 10 before age 20.
Ten of the 14 individuals carrying the disease-associated
haplotype were already affected at the time of the study (Fig 1).
Two of the remaining individuals with this haplotype (II-1 and II-
5) were scored as unknown for linkage analysis purposes even
though they had affected offspring, because they were not
examined. Moreover, II-5 suffered from abdominal pains and
died from a suspected uterine tumor during labor, at age 34.
Finally, V-2 and V-17 are 19 and 18 y old, respectively, thus they
are still too young to draw any de®nitive conclusion. The rest of
family members classi®ed as unknown (IV-15 through IV-21),
ranging in age from 24 to 42 y old and coded as unknown because
their mother developed the cutaneous disease at age 45, as well as
the children in the last generation, all under age 21, have inherited
the wild-type chromosome from their affected parent (Fig 1).
The data presented in this study show that MCUL1 is inherited
as an autosomal dominant gene with high penetrance, in accord-
ance with Alam et al (2001). In their pedigrees, seven unaffected
individuals, aged 28±67, carry the disease-associated haplotype. The
results reported by Launonen et al (2001), on the other hand, show
a more complex scenario. Although they have identi®ed one single
unaffected carrier (unspeci®ed age), only 14 of 16, seven of 16, and
six of 16 carriers have developed uterine leiomyoma/leiomyosar-
coma, cutaneous leiomyomas, and renal cell cancer, respectively.
Figure 2. Clinical ®ndings in the MCL pedigree. In most family
members, the disease begins with leiomyomas on the left upper arm
(patient IV-3: a).The disease then progresses to the left upper back and
right upper back (patient III-17: b), and then to the middle and lower
right back (patient III-17: c).
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The MCUL1 interval includes several known genes, as well as
many unknown expressed sequence tags, although there is no
obvious candidate among them (Human Genome Project Working
Draft; National Center for Biotechnology Information; Ensembl
Genome Server; GeneMap'99). The further re®nement of the
critical linkage interval will be needed to de®ne the exact location
of the MCUL1 locus, as well as to elucidate the possibility of
heterogeneity on the genetic predisposition to MCL. It is of interest
that both LOH (Mao et al, 1999) and balanced translocations
(Mitelman et al, 1997) have been reported in uterine leiomyomas
involving the chromosomal region 1q42.
The recent reports on the identi®cation of the MCUL1 locus,
together with the data presented here may provide valuable insights
into the etiology and genetic causes of skin and uterine
leiomyomas, the latter being a major health issue for women. Its
association with the more aggressive renal cell cancer (Kiuru et al,
2001; Launonen et al, 2001) may facilitate early patient identi®-
cation. Finally, the development of new drugs and treatments may
be achieved once the molecular basis of these tumors is established.
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